Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO

Century Therapeutics, Inc.

2023-Q3 EPS reported -$1.65 revenue$1,967,000

Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.
Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.
Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.
Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.
Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Century Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $0.1 million, net income $32.7 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $0.1 million
Net income: $32.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(BMS) collaboration of $118.5 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option, and license agreement with BMS was $0.1 million for the three months ended September 30, 2023 compared to $2.2 million for the same period in 2022. Revenue recognized under the collaboration agreement fluctuates based on the

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.